Table 3.
Circulating miRNA expression levels before and after angioplasty in the angioplasty cohort, according to patent and restenosis groups at 6 months after angioplasty
miRNAs | Patent (n=32) | Restenosis (n=28) | P Value | ||
---|---|---|---|---|---|
MiR-21 | |||||
Before | 0.76 | (0.23–2.08) | 1.06 | (0.30–5.45) | 0.22 |
After | 1.31 | (0.40–4.16) | 2.39 | (1.11–12.62) | 0.02 |
Δ(after-before) | 0.22 | (0.12–0.88) | 0.91 | (0.48–3.53) | <0.001 |
MiR-130a | |||||
Before | 0.75 | (0.24–2.67) | 1.67 | (0.65–4.40) | 0.09 |
After | 2.10 | (1.08–6.32) | 4.61 | (2.34–7.18) | 0.04 |
Δ(after-before) | 1.14 | (0.30–2.48) | 1.97 | (1.32–3.87) | 0.04 |
MiR-221 | |||||
Before | 0.76 | (0.14–3.35) | 1.42 | (0.43–10.31) | 0.21 |
After | 1.93 | (0.51–4.92) | 2.62 | (1.49–15.73) | 0.96 |
Δ(after-before) | 0.50 | (0.20–1.21) | 0.82 | (0.46–1.48) | 0.21 |
MiR-222 | |||||
Before | 1.24 | (0.28–3.37) | 1.12 | (0.57–1.63) | 0.12 |
After | 1.16 | (0.35–2.71) | 1.15 | (0.49–1.75) | 0.05 |
Δ(after-before) | −0.03 | (−0.23 to 0.42) | 0.16 | (−0.44 to 0.79) | 0.12 |
MiR-133 | |||||
Before | 3.23 | (0.91–5.43) | 3.01 | (1.43–5.06) | 0.69 |
After | 2.19 | (1.31–4.63) | 4.47 | (1.55–8.58) | 0.30 |
Δ(after-before) | 0.25 | (−1.26 to 1.90) | 2.27 | (0.02–4.72) | 0.11 |
MiR-145 | |||||
Before | 1.38 | (0.28–4.13) | 1.43 | (0.75–3.23) | 0.79 |
After | 2.40 | (0.96–6.16) | 2.34 | (1.13–5.38) | 0.87 |
Δ(after-before) | 1.07 | (0.24–2.83) | 0.67 | (−0.13 to 4.02) | 0.61 |
Data were expressed as median (interquartile range). Unit of miRNA expression levels: relative quantities, the relative expression level of miRNAs determined by the cycle number via quantitative real-time PCR, normalized to a control miRNA cel-miR-39 expression. miRNA, microRNA; Before, value before angioplasty; After, value 2 days after angioplasty; Δ (after-before): value 2 days after angioplasty minus value before angioplasty.